Your browser doesn't support javascript.
Nothing really changed: Arizona patient experience of methadone and buprenorphine access during COVID.
Meyerson, Beth E; Bentele, Keith G; Russell, Danielle M; Brady, Benjamin R; Downer, Missy; Garcia, Roberto C; Garnett, Irene; Lutz, Rebecca; Mahoney, Arlene; Samorano, Savannah; Arredondo, Christina; Andres, Honey J; Coles, Haley; Granillo, Brenda.
  • Meyerson BE; Southwest Institute for Research on Women, College of Social and Behavioral Sciences University of Arizona, Tucson, Arizona, United States of America.
  • Bentele KG; Family and Community Medicine, College of Medicine, University of Arizona, Tucson, Arizona, United States of America.
  • Russell DM; Southwest Institute for Research on Women, College of Social and Behavioral Sciences University of Arizona, Tucson, Arizona, United States of America.
  • Brady BR; School of Social Transformation, Arizona State University, Tempe, Arizona, United States of America.
  • Downer M; Center for Rural Health, Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, Arizona, United States of America.
  • Garcia RC; Comprehensive Pain and Addiction Center, University of Arizona, Tucson, Arizona, United States of America.
  • Garnett I; Southwest Recovery Alliance, Phoenix, Arizona, United States of America.
  • Lutz R; Drug Policy Research and Advocacy Board, Tucson, Arizona, United States of America.
  • Mahoney A; Sonoran Prevention Works, Phoenix, Arizona, United States of America.
  • Samorano S; Drug Policy Research and Advocacy Board, Tucson, Arizona, United States of America.
  • Arredondo C; Drug Policy Research and Advocacy Board, Tucson, Arizona, United States of America.
  • Andres HJ; Southwest Recovery Alliance, Phoenix, Arizona, United States of America.
  • Coles H; Drug Policy Research and Advocacy Board, Tucson, Arizona, United States of America.
  • Granillo B; Drug Policy Research and Advocacy Board, Tucson, Arizona, United States of America.
PLoS One ; 17(10): e0274094, 2022.
Article in English | MEDLINE | ID: covidwho-2089400
ABSTRACT

OBJECTIVE:

To understand patient experience of federal regulatory changes governing methadone and buprenorphine (MOUD) access in Arizona during the COVID-19 pandemic.

METHODS:

This community-based participatory and action research study involved one-hour, audio-recorded field interviews conducted with 131 people who used methadone and/or buprenorphine to address opioid use disorder at some point during COVID (January 1, 2020- March 31, 2021) in Arizona. Transcribed data were analyzed using a priori codes focused on federally recommended flexibilities governing MOUD access. Data were quantitated to investigate associations with COVID risk and services access.

RESULTS:

Telehealth was reported by 71.0% of participants, but the majority were required to come to the clinic to attend video appointments with an offsite provider. Risk for severe COVID outcomes was reported by 40.5% of the sample. Thirty-eight percent of the sample and 39.7% of methadone patients were required to be at the clinic daily to get medication and 47.6% were at high risk for COVID severe outcomes. About half (54.2%) of methadone patients indicated that some form of multi-day take home dosing was offered at their clinic, and 45.8% were offered an extra day or two of multi-day doses; but no participants received the federally allowed 14- or 28-day methadone take-home doses for unstable and stable patients respectively. All participants expressed that daily clinic visits interrupted their work and home lives and desired more take-home dosing and home delivery options.

CONCLUSIONS:

MOUD patients in Arizona were not offered many of the federally allowed flexibilities for access that were designed to reduce their need to be at the clinic. To understand the impact of these recommended treatment changes in Arizona, and other states where they were not well implemented, federal and state regulators must mandate these changes and support MOUD providers to implement them.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Buprenorphine / COVID-19 / COVID-19 Drug Treatment / Opioid-Related Disorders Type of study: Observational study / Prognostic study / Qualitative research Limits: Humans Country/Region as subject: North America Language: English Journal: PLoS One Journal subject: Science / Medicine Year: 2022 Document Type: Article Affiliation country: Journal.pone.0274094

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Buprenorphine / COVID-19 / COVID-19 Drug Treatment / Opioid-Related Disorders Type of study: Observational study / Prognostic study / Qualitative research Limits: Humans Country/Region as subject: North America Language: English Journal: PLoS One Journal subject: Science / Medicine Year: 2022 Document Type: Article Affiliation country: Journal.pone.0274094